DVA Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 6.58% compared to DaVita's net margin of 11.12%. DaVita's return on equity of 32.21% beat Boston Scientific's return on equity of 8.91%.

DaVita has a consensus price target of $148.44, signalling upside risk potential of 3.33%. On the other hand Boston Scientific has an analysts' consensus of $99.00 which suggests that it could grow by 11.3%. Given that Boston Scientific has higher upside potential than DaVita, analysts believe Boston Scientific is more attractive than DaVita.

DaVita has a beta of 0.899, which suggesting that the stock is 10.057% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.802, suggesting its less volatile than the S&P 500 by 19.799%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DaVita pays -- of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Boston Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DaVita quarterly revenues are $3.3B, which are smaller than Boston Scientific quarterly revenues of $4.2B. DaVita's net income of $214.7M is lower than Boston Scientific's net income of $468M. Notably, DaVita's price-to-earnings ratio is 16.38x while Boston Scientific's PE ratio is 73.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 1.07x versus 8.29x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Quest Diagnostics has a net margin of 6.58% compared to DaVita's net margin of 9.08%. DaVita's return on equity of 32.21% beat Quest Diagnostics's return on equity of 12.68%.

DaVita has a consensus price target of $148.44, signalling upside risk potential of 3.33%. On the other hand Quest Diagnostics has an analysts' consensus of $169.77 which suggests that it could grow by 10.89%. Given that Quest Diagnostics has higher upside potential than DaVita, analysts believe Quest Diagnostics is more attractive than DaVita.

DaVita has a beta of 0.899, which suggesting that the stock is 10.057% less volatile than S&P 500. In comparison Quest Diagnostics has a beta of 0.893, suggesting its less volatile than the S&P 500 by 10.74%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics offers a yield of 1.93% to investors and pays a quarterly dividend of $0.75 per share. DaVita pays -- of its earnings as a dividend. Quest Diagnostics pays out 36.77% of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DaVita quarterly revenues are $3.3B, which are larger than Quest Diagnostics quarterly revenues of $2.5B. DaVita's net income of $214.7M is lower than Quest Diagnostics's net income of $226M. Notably, DaVita's price-to-earnings ratio is 16.38x while Quest Diagnostics's PE ratio is 20.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 1.07x versus 1.80x for Quest Diagnostics. Usually stocks with elevated PS ratios are considered overvalued.

Encompass Health has a net margin of 6.58% compared to DaVita's net margin of 8.01%. DaVita's return on equity of 32.21% beat Encompass Health's return on equity of 17.39%.

DaVita has a consensus price target of $148.44, signalling upside risk potential of 3.33%. On the other hand Encompass Health has an analysts' consensus of -- which suggests that it could grow by 23.35%. Given that Encompass Health has higher upside potential than DaVita, analysts believe Encompass Health is more attractive than DaVita.

DaVita has a beta of 0.899, which suggesting that the stock is 10.057% less volatile than S&P 500. In comparison Encompass Health has a beta of 0.876, suggesting its less volatile than the S&P 500 by 12.393%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Encompass Health offers a yield of 0.66% to investors and pays a quarterly dividend of $0.17 per share. DaVita pays -- of its earnings as a dividend. Encompass Health pays out 17.16% of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DaVita quarterly revenues are $3.3B, which are larger than Encompass Health quarterly revenues of $1.4B. DaVita's net income of $214.7M is higher than Encompass Health's net income of $108.2M. Notably, DaVita's price-to-earnings ratio is 16.38x while Encompass Health's PE ratio is 22.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 1.07x versus 1.85x for Encompass Health. Usually stocks with elevated PS ratios are considered overvalued.

HCA Healthcare has a net margin of 6.58% compared to DaVita's net margin of 7.26%. DaVita's return on equity of 32.21% beat HCA Healthcare's return on equity of 616.06%.

DaVita has a consensus price target of $148.44, signalling upside risk potential of 3.33%. On the other hand HCA Healthcare has an analysts' consensus of $398.84 which suggests that it could grow by 31.36%. Given that HCA Healthcare has higher upside potential than DaVita, analysts believe HCA Healthcare is more attractive than DaVita.

DaVita has a beta of 0.899, which suggesting that the stock is 10.057% less volatile than S&P 500. In comparison HCA Healthcare has a beta of 1.632, suggesting its more volatile than the S&P 500 by 63.178%.

DaVita has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HCA Healthcare offers a yield of 0.87% to investors and pays a quarterly dividend of $0.66 per share. DaVita pays -- of its earnings as a dividend. HCA Healthcare pays out 12.61% of its earnings as a dividend. HCA Healthcare's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

DaVita quarterly revenues are $3.3B, which are smaller than HCA Healthcare quarterly revenues of $17.5B. DaVita's net income of $214.7M is lower than HCA Healthcare's net income of $1.3B. Notably, DaVita's price-to-earnings ratio is 16.38x while HCA Healthcare's PE ratio is 13.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita is 1.07x versus 1.16x for HCA Healthcare. Usually stocks with elevated PS ratios are considered overvalued.